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Abstract
Background: Traumatic brain injury (TBI) is a major cause of CNS neurodegeneration and has no disease-altering
therapies. It is commonly associated with a specific type of biomechanical disruption of the axon called traumatic
axonal injury (TAI), which often leads to axonal and sometimes perikaryal degeneration of CNS neurons. We have
previously used genome-scale, arrayed RNA interference-based screens in primary mouse retinal ganglion cells
(RGCs) to identify a pair of related kinases, dual leucine zipper kinase (DLK) and leucine zipper kinase (LZK) that are
key mediators of cell death in response to simple axotomy. Moreover, we showed that DLK and LZK are the major
upstream triggers for JUN N-terminal kinase (JNK) signaling following total axonal transection. However, the degree
to which DLK/LZK are involved in TAI/TBI is unknown.
Methods: Here we used the impact acceleration (IA) model of diffuse TBI, which produces TAI in the visual system,
and complementary genetic and pharmacologic approaches to disrupt DLK and LZK, and explored whether DLK
and LZK play a role in RGC perikaryal and axonal degeneration in response to TAI.
Results: Our findings show that the IA model activates DLK/JNK/JUN signaling but, in contrast to axotomy, many
RGCs are able to recover from the injury and terminate the activation of the pathway. Moreover, while DLK disruption
is sufficient to suppress JUN phosphorylation, combined DLK and LZK inhibition is required to prevent RGC cell death.
Finally, we show that the FDA-approved protein kinase inhibitor, sunitinib, which has activity against DLK and LZK, is
able to produce similar increases in RGC survival.
Conclusion: The mitogen-activated kinase kinase kinases (MAP3Ks), DLK and LZK, participate in cell death signaling of
CNS neurons in response to TBI. Moreover, sustained pharmacologic inhibition of DLK is neuroprotective, an effect
creating an opportunity to potentially translate these findings to patients with TBI.
Keywords: Traumatic axonal injury, Concussion, Cell death, Traumatic brain injury, Optic neuropathy, Dual leucine
zipper kinase, DLK, LZK, Retinal ganglion cell
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Background
Traumatic brain injury (TBI) affects over 2.5 million
people each year in the U.S. alone, and is associated with
lasting deficits in motor, sensory, and higher CNS func-
tions [1]. As of yet, there are no therapies that prevent
or alter the course of these conditions and, thus, there is
an urgent need to better understand the molecular path-
ways that are responsible for the underlying neuropath-
ology and then develop disease-modifying drugs. A very
common pathology in TBI of various causes and degrees
of severity is diffuse or traumatic axonal injury (TAI)
[2–6]. TAI is thought to be caused by rotational acceler-
ation of the head resulting in extremely rapid axonal
stretching in multiple white matter foci in the forebrain
and brain stem. We and others have shown that TAI
can be modeled in the rodent brain with specifically ar-
ranged impact forces [7–12].
A consistent finding in multiple TBI models, including
blunt force models such as fluid percussion and impact
acceleration (IA) as well as blast, is the presence of TAI
in the optic nerve and optic tract [11, 13–15]. This inter-
esting observation, combined with the accessibility and
compartmentalized anatomy of the visual system, sug-
gests that retinal ganglion cells (RGCs) are an excellent
neuronal system in which to model TAI and explore the
underlying cellular and molecular mechanisms.
We have previously identified the key mediators in-
volved in RGC axon injury signaling in primary mouse
RGCs with a high-throughput, functional genomic screen.
Using small interfering RNAs (siRNAs) to knockdown
gene expression, we screened through the mouse genome
and, along with others, identified a multi-tiered kinase cas-
cade that is responsible for axon injury signaling in vitro
and in vivo [16–19]. This cascade includes the mitogen-
activated protein kinase kinase kinases (MAP3Ks) dual
leucine zipper kinase (DLK/MAP3K12) and leucine zipper
kinase (LZK/MAP3K13), the mitogen-activated protein
kinase kinases (MAP2Ks) MKK4/MAP2K4 and MKK7/
MAP2K7, and the mitogen-activated protein kinases
(MAPKs) JUN N-terminal kinase (JNK) 1–3. In response
to optic nerve crush (ONC), DLK is robustly upregulated
at the site of axonal injury and is transported to the soma
where it initiates a toxic genetic program mediated by
multiple transcription factors including JUN [16, 17, 20,
21]. While DLK inhibition is sufficient to reduce cell death
after axonal injury, combined DLK and LZK inhibition
leads to a more robust protective phenotype suggesting
some degree of redundancy [18]. Moreover, there is still
uncertainty as to the degree of participation of DLK in the
degeneration of axons following injury [16, 17, 22–24]. To
the extent that TAI in various models of TBI, including
IA, engages this same injury signaling cascade, DLK/LZK
inhibition could become part of a neuroprotective treat-
ment strategy for TBI.
In the present study, we explore the activation of
DLK/LZK signaling in RGCs in the course of TAI in the
mouse visual system inflicted with IA. We then establish
the role of this kinase pathway in RGC somal and axonal
degeneration with genetic and pharmacological strat-
egies designed to block DLK and LZK. Our results indi-
cate that the DLK/LZK-JNK axis is robustly involved in
RGC death associated with TAI in the visual system and
suggest a broader role of this kinase cascade in primary
axonopathies associated with TBI.
Methods
Experimental subjects and IA procedures
Eight-week-old male C57BL/6 J wild-type mice and
transgenic Dlkfl/fl and Dlkfl/flLzkfl/fl mice were subjected
to IA or sham injury. Male mice were chosen such as to
avoid the confounding effects of sex hormones on injury
outcomes [25–29]. Wild-type mice and founders were
purchased from Charles River Laboratories (Wilmington,
MA). Animals were housed in a vivarium with a 12-h
light/12-h dark cycle and given ad libitum access to food
and water. All animal handling as well as surgical and
postoperative procedures were carried out according to
protocols approved by the Animal Care and Use Com-
mittee of the Johns Hopkins Medical Institutions.
Impact acceleration injury was performed with height-
weight settings generating kinetic energy of 0.45–0.5 J
upon impact, essentially as described [11, 12] (Table 1).
Immediately prior to injury, the cranium was exposed
and a 5 mm-thick stainless-steel disc was glued onto the
skull midway between bregma and lambda sutures. Sur-
gical procedures and injury were performed under asep-
tic conditions with gas anesthesia (isoflurane: oxygen:
nitrous oxide = 1:33:66). Immediately after injury the disc
was removed the skull was checked under the surgical
microscope for skull fractures. The rare animals with
skull fractures were excluded from further study because
such events introduce injuries variables that cannot be
easily controlled. Sham animals were subjected to the
same procedures, but without the weight drop. The scalp
incision was closed with surgical staples, and the animal
was returned to cage.
Histology, histochemistry, immunohistochemistry and
microscopy
At the various survival times listed in Table 1, animals
were transcardially perfused with freshly depolymerized,
4% neutral-buffered paraformaldehyde. Eyes were enu-
cleated and fixed for 2 h while optic nerves were
immersed in the same fixative overnight at 4 °C. In some
cases, brains were also included in the study for the ana-
lysis of optic tracts and superior colliculi. Tissues were
cryoprotected in 30% sucrose and stored at − 80 °C until
further processing. Sagittal brain sections (40 μm), some
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with attached distal nerves, were prepared in series
for Gallyas silver staining for injured/degenerating
axons and terminals and immunohistochemistry (IHC)
for the microglial marker IBA1. Gallyas silver staining
was performed as described [14]. Sagittal retinal sec-
tions (10 μm) were prepared on a cryostat and proc-
essed in series for immunoperoxidase-based IHC to
assay for select members of the DLK-JNK pathway,
including DLK, phosphorylated JNK (p-JNK) and
phosphorylated JUN (p-JUN). Sagittal sections of the
entire optic nerve were used to assay for the presence
of axon injury and blood brain barrier (BBB) disrup-
tion at early time points post-injury, with amyloid
precursor protein (APP) and IgG staining, as de-
scribed [11]. Retinal flat mounts were prepared as de-
scribed [11] and used to explore injury responses or
survival of RGCs based on p-JUN and γ-synuclein
(SNCG) immunofluorescence.
Table 1 Impact acceleration condition and survival time for each experimental group
Experiments/groups Experimental history, survival times post-IA Procedures
1.Characterization of initial injury in the optic nerve - general Sham (n = 3), 4 h post-IA (n = 3), 24 h
post-IA (n = 3)
IA:40 g × 1 m or 60 g × 0.85 m
IHC for APP (TAI) and IgG (BBB disruption)
2. Characterization of initial injury in the optic nerve
- CLARITY
CTB injection immediately post-IA, survival
2 d post-IA (n = 3)
IA: 40 g × 1m -– 60 g × 0.85 m
CLARITY
3. Characterization of traumatic axonopathy - general
neuropathology in the optic nerve and tract
7 d post-IA (n = 3)
IA:40 g × 1 m or 60 g × 0.85 m
Gallyas silver
IHC for neuroinflammation (IBA1)
4. Characterization of traumatic axonopathy - death of RGCs
in retina
Sham (n = 6), 2 wk. post-IA (n = 7), 4 wk.
post-IA (n = 5)
IA:40 g × 1 m
IHC for γ Synuclein
Cell counts on retinal wholemounts
5. Characterization of traumatic axonopathy - axonal
degeneration in optic nerve
Sham (n = 6), 2 wk. post-IA (n = 7), 4 wk.
post-IA (n = 5)
IA:40 g × 1 m
Embedding of optic nerve tissues in
epoxy resin, semithin sectioning, toluidine
blue staining
6. Induction of DLK-JNK pathway in RGCs after injury 24 h (n = 3), 3 d post-IA (n = 3)
IA:40 g × 1 m
IHC for DLK, p-JUN in retinal sections
7. Time course of DLK-JNK induction in RGCs after injury Sham (n = 4), 24 h post-IA (n = 10), 3 d
post-IA (n = 5), 7 d post-IA (n = 4), 14 d
post-IA (n = 3)
IA:40 g × 1 m
IHC for γ Synuclein and p-JUN
Cell counts on retinal wholemounts
8. Time course of activation of distinct member of DLK-JNK
pathway in RGCs after injury
Sham (n = 3), 24 h post-IA (n = 3), 3 d
post-IA (n = 3), 7 d post-IA (n = 3)
IA:40 g × 1 m
Standard Western blotting
9. Interventional studies - genetic deletion of Dlk on Dlkfl/fl
mice and effects on DLK-JNK pathway activation and RGC
survival
AAV2-Cre-GFP into one eye
AAV2-GFP into fellow eye
(n = 4 each, injections 2 wk. pre-IA, eu-
thanasia 3 days post-IA)
IA:60 g × 0.85 m
IHC for p-JUN
Cell counts on retinal wholemounts
AAV2-Cre-GFP into one eye
AAV2-GFP into fellow eye
(n = 7 each, injections 2 wk. pre-IA, eu-
thanasia 4 wk. post-IA)
IA:60 g × 0.85 m
IHC for RBPMS
Cell counts on retinal wholemounts
10. Interventional studies - genetic deletion of Dlk and Lzk
on Dlkfl/flLzkfl/fl and effects on DLK-JNK pathway activation
and RGC survival
AAV2-Cre-GFP into one eye
AAV2-GFP into fellow eye
(n = 4 each, injections 2 wk. pre-IA, eu-
thanasia 3 day post-IA)
IA:60 g × 0.85 m
IHC for p-JUN
Cell counts on retinal wholemounts
AAV2-Cre-GFP into one eye
AAV2-GFP into fellow eye
(n = 7 each, injections 2 wk. pre-IA, eu-
thanasia 4 wk. post-IA)
IA:60 g × 0.85 m
IHC for RBPMS
Cell counts on retinal wholemounts
11. Interventional studies - pharmacologic kinase inhibition
with sunitinib and effects on DLK-JNK pathway activation
and RGC survival
Drug (n = 12)
Vehicle (n = 14),
both groups 3 wk. post-IA
IA:40 g × 1 m
IHC for γ Synuclein
Cell counts on retinal wholemounts
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In all experiments involving IHC, sections were first
incubated in the primary antibody overnight at 4 °C. For
immunoperoxidase staining, after incubation with bio-
tinylated secondary antibody (1:200; Jackson ImmunoRe-
search, West Grove, PA) and then avidin and
biotinylated peroxidase, sections were developed with 3,
3′-diaminobenzidine (DAB) (Vectastain Elite ABC Kit;
Vector Laboratories Inc., Burlingame, CA). For immuno-
fluorescence, after incubation in secondary antibodies
conjugated with Cy3 or Cy2 (1:200; Jackson ImmunoRe-
search, West Grove, PA) for 2–4 h at room temperature,
sections were counterstained with the fluorescent DNA
dye 4′, 6-diamidino-2-phenylindole (DAPI) and cover-
slipped with DPX. Primary antibodies included: anti-
IBA1 (1:500; Dako; 019–19,741, Carpinteria, CA or
Biocare Medical; CP-290A, Pacheco, CA); DLK (1:200,
GeneTex; GTX124127, Irvine, CA); p-JNK (1:200, Cell
Signaling Technology; 9251 or 4671, Danvers, MA); p-
JUN (1:200, Cell Signaling Technology; 9261 or 3270,
Danvers, MA); SNCG (1:600; Abnova; H00006623-M01,
Walnut, CA or Genetex; GTX110483, Irvine, CA);
RBPMS (1:1000, PhosphoSolutions; 1832-RBPMS or
1830-RBPMS, Aurora, CO); and TUJ1 (1:600, Covance;
MMS-435P or PRB-435P, Indianapolis, IN or Abcam;
ab18207, Cambridge, MA). Immunostained sections
were studied on a Zeiss Axiophot microscope equipped
for epifluorescence or a Zeiss LSM 510 inverted confocal
microscope. Adobe Photoshop 9.0 software (Adobe Sys-
tems, San Jose, CA) was used for image processing.
CLARITY-based processing of the optic nerve
To explore the location and extent of axonal injury in the
optic nerve after IA, the anterograde tracer cholera toxin
subunit B (CTB) conjugated with Alexa Fluor® 488 (CTB
488) was injected intravitreally 1 h after IA or sham injury.
Optic nerves were then dissected and processed by CLAR-
ITY as described [12]. In brief, optic nerves were incu-
bated in a hydrogel containing 2% acrylamide, 0.025% bis-
acrylamide, 0.25% VA-044 initiator and 4% PFA in 0.1M
PBS overnight (4 °C). After degassing, samples were incu-
bated in a water bath (37 °C) for 3 h. Polymerized nerves
were then transferred to a boric acid solution with 4%
SDS and were incubated for 4 days. Prior to imaging, optic
nerves were incubated in FocusClear (CellExplorer catalog
#FC-101) and mounted for imaging. Transparent optic
nerves were imaged with confocal microscopy at 20× on a
Zeiss AxioExaminer microscope with a 710NLO module
(Carl Zeiss Inc., Oberkochen, Germany) and images were
visualized with Imaris software (Bitplane, Concord, MA).
Semithin-section processing of the optic nerve
Optic nerves from sham- and IA-injured subjects
were dissected away from the eyes and brains and
treated with a solution containing 4%
paraformaldehyde and 0.2% glutaraldehyde for 24 h.
After rinsing in 0.1 M phosphate buffer (pH 7.3) for
3–10 min, tissues were immersed in 1% osmium tet-
roxide for 15 min and stained en bloc with 1% uranyl
acetate for 1 h. Stained tissues were dehydrated in
graded concentrations of ethanol, embedded in Poly/
Bed 812 (Polysciences Inc., Warrington, PA) in
BEEM® capsules and polymerized at 60 °C for 72 h.
Semithin sections (1 μm) were cut transversely from
segments of optic nerves caudal to the eyeball and
stained with 1% toluidine blue. Myelinated axonal
profiles were studied under 100× magnification on a
Zeiss Axiophot microscope equipped for epifluores-
cence (Diagnostic Instruments Inc., Sterling Heights,
MI); normal profiles were counted by investigators
blinded to experimental history using the optical frac-
tionator probe in the Stereo Investigator® software
(Microbrightfield Inc., Williston, VT).
Immunoblots
To explore the involvement of select members of the DLK-
JNK axis in visual TAI after IA, we harvested fresh eyeballs at
days 1, 3 and 7 after injury and then dissected the retinas and
stored them at − 80 °C. For protein extraction, retinas were
sonicated in cell lysis buffer containing 1mM PMSF (Cell Sig-
naling Technology, Danvers, MA), complete protease inhibi-
tor cocktail and PhosSTOP phosphatase inhibitor cocktail
(Roche, Basel, Switzerland) and then incubated for 30min at
room temperature. Solubilized proteins in Laemmli sample
buffer were separated on SDS-PAGE gel and then transferred
to polyvinylidene fluoride (PVDF) membranes using XCell II
blot system (Invitrogen, Carlsbad, CA). Membranes were
blocked with 5% Bovine Serum Albumin (BSA) in Tris-
buffered saline/0.05% Tween-20 and sequentially incubated in
primary antibodies (overnight, 4 °C). In addition to DLK, p-
JNK and p-JUN (all at 1:1000) antibodies that were the same
as in previous section, we also used antibodies against phos-
phorylated MKK4 and MKK7 (1:1000, Cell Signaling Tech-
nology, Danvers, MA), and a β-actin antibody (1:1000, Cell
Signaling Technology, Danvers, MA). HRP-conjugated sec-
ondary antibody (1 h at RT) and SuperSignal Chemilumines-
cent Substrate (Thermo Scientific. Reckford, IL) was used to
detect protein signals. Image J (National Institutes of Health)
and Prism (GraphPad Software, Inc., La Jolla, CA) were used
for quantitation and statistical analysis.
Dlk/Lzk knockout in Dlkfl/fl and Dlkfl/flLzkfl/fl mice
Male Dlkfl/fl and Dlkfl/flLzkfl/fl mice were subjected to
IA as described above [11, 12]. Two weeks prior to
injury, subjects were intravitreally injected in one eye
with AAV2 expressing Cre-GFP (AAV-Cre) and in
the fellow eye with AAV2 expressing GFP (AAV-
GFP). In one set of experiments (n = 5 per Dlkfl/fl,
Dlkfl/fl Lzkfl/f and wild-type mice), 3 days after injury,
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retinal flat mounts were immunostained for p-JUN
and taken for counts of immunoreactive neurons as
laid out in previous sections, with the AAV2-GFP-
injected eye serving as control. In another experimen-
tal scenario (n = 9–10 per Dlkfl/fl, Dlkfl/fl Lzkfl/fl and
wild-type mice) animals were allowed to survive for 3
weeks and retinal flat mounts were processed for
counts of SNCG-positive or RBPMS-positive RGCs as
described in previous Sections.
DLK-JNK inhibition with the protein kinase inhibitor
sunitinib
Sunitinib stock solution was made by dissolving drug
powder in dimethylsulfoxide (DMSO) at a concentration
of 120 mg/ml and was stored at − 20 °C. At the time of
drug administration, stock solution was diluted with sa-
line to a final concentration of 6 mg/ml and injected in-
traperitoneally into mice (60 mg/kg). Sunitinib was
administered 24 and 4 h prior to injury, and then once
Fig. 1 Location of the initial optic nerve disruption injury in IA-injured animals. a-c. Early axonal and BBB changes as shown with double immunofluorescence
for APP (green) and mouse IgG (red). Eyeball is to the left, optic chiasm to the right of panel. Four hours after injury, there are multiple axonal swellings and
bulbs (green), evidence of primary TAI at approximately 2/3 of optic nerve from the eyeball. There is also disruption of BBB manifested by IgG leakage (red) in
the same area but covering a larger segment of the nerve. There are no APP (+) axonal abnormalities or BBB disruption in the optic nerve of sham mice. Insets
show representative lesions in two magnifications at four (b) and 24 (c) hours post-injury. d. Disruption of CTB transport in optic nerve after IA injury: Axonal
transport in optic nerve was explored by intravitreally injecting CTB488 1 h after injury. Processed with CLARITY 2 days after injury, CTB-488 (green) transport is
interrupted at approximately 2/3 of the optic nerve from the eyeball at exactly the same site as APP (+) axonal abnormalities and BBB alterations in a-c. e-f.
Details of axonal abnormalities at the level of initial mechanical nerve disruption. Panels are magnifications of identically labeled regions in b, c, and d. Note
classical axonal bulbs 4 h post-injury (e), varicosities and undulations at 24 h (f), and the interrupted axonal transport of CTB in most axons in (g). Scale bars: a-c,
500μm; d, 550μm; e-g, 50μm
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more immediately after the injury (for the evaluation of
p-JUN expression in RGCs) or daily for 3 weeks starting
immediately after the injury (for the evaluation of RGC
survival). Control animals received injections of vehicle
solution.
RGC counts in retinal flatmounts
The four quadrants of retinal mounts immunolabeled with
SNCG and p-JUN were separately imaged with a 20× ob-
jective (0.4 numerical aperture) on a Zeiss LSM 510
inverted confocal microscope (Carl Zeiss Inc., Oberko-
chen, Germany). Images were adjusted for optimal
contrast and brightness with Adobe Photoshop 7.0 and
Image J was used to count surviving SNCG (+), RBPMS
(+) or injured p-JUN (+) RGCs. Cells were counted in
150 × 150 μm fields from three concentric zones of the
same width, from the center to the periphery of the retina,
using at least 8 fields per each zone. Cell density was cal-
culated by dividing cell numbers by total area surveyed.
The ratio of p-JUN (+) RGCs cells was calculated by divid-
ing the number of p-JUN/SNCG double-labeled cells by
the total number of SNCG (+) cells. In a number of exper-
iments, i.e. p-JUN response and survival of RGCs in Dlkfl/fl
and Dlkfl/flLzkfl/fl mice and RGC survival in the sunitinib
Fig. 2 Axonal degeneration (Gallyas silver) and neuroinflammation in the visual system after IA injury. a-d. Gallyas silver degeneration staining shows axonal
pathology (black swellings, lines, trails, dots) 7 days after injury in the optic nerve (ON, a), optic tract (OT, b), and superior colliculus (SC, c). Sham tissues show no
silver signal at the same time point (d). e-f. Neuroinflammatory responses are evident by the presence of hypertrophic IBA1 (+) microglia and microglial
nodules in these sections prepared 7 days after injury. Note the striking selectivity of neuroinflammation in the visual system (optic nerve [ON] and optic tract
[OT]) by comparing IBA1 (+) profiles in ON and OT to normal resting microglia in overlying hypothalamus. Scale bars: a-d, 100μm; e, 80μm; f, 150μm
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experiment, counts were done using an automated image
analysis system (ImageXpress high content imager, Mo-
lecular Devices, Sunnyvale CA) using the autofocus and
auto-tiling function at 20× magnification followed by
automatic quantification with ImageJ.
Statistical methodologies
Statistical analysis was carried out with one-way
ANOVA or t test. In the case of ANOVA, significant dif-
ferences were further analyzed with Tukey’s post hoc
test to reveal important main effects or interactions. For
Fig. 3 Axonal degeneration in the proximal and distal optic nerve following IA injury. Axonal pathology in the optic nerve of mice was examined
with toluidine blue staining of semithin sections from sham (a) and 2- or 4-week post-injury cases (b and c, respectively). The nerve segment
proximal to initial traumatic disruption is on the left, distal to disruption segment (close to chiasm) is on the right. Within the first month, there is
evident axonopathy, distal more than proximal. In both segments and time points, pathology is more severe at the center of the nerve. Fields are
further enlarged for greater cellular detail in Fig. 4. Panel d is a bar graph with stereological counts of normal axons in the proximal and distal
segments of the optic nerve in the sham condition and at 2 and 4 weeks post injury. Numbers are expressed as percentages of sham because
there is a difference in baseline myelinated axons in the proximal and distal segments in this experiment where proximal sections were taken
from a plane ~ 0.5–1 mm posterior to the eye. Scale bars: 100 μm
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counts of axonal number in the characterization of
optic neuropathy, numbers were normalized to sham
mean. Calculations were performed using Prism 4
(GraphPad Software). Differences were considered sig-
nificant at p < 0.05.
Results
Traumatic axonal injury in the visual system is associated
with RGC axonopathy and axonal degeneration
To characterize the initial effect of IA on the optic nerve,
sections were immunostained for amyloid precursor pro-
tein (APP), a marker of early TAI. As early as 4 h after in-
jury, we found a distinct region of APP-positive swellings
and bulbs between the orbital apex and the chiasm
(Fig. 1a-c). Amyloid precursor protein colocalized with
IgG immunoreactivity, indicating serum extravasation and
blood-brain barrier (BBB) disruption (Fig. 1b-c). Axonal
abnormalities included classical axon bulbs and varicosi-
ties (Fig. 1e-f). When retinas were injected with CTB488
and optic nerves processed with CLARITY to visualize
transport in the nerve, we identified CTB488 transport
blockade in the same location of the nerve that had APP-
positive axonal abnormalities (Fig. 1d, g). These findings
indicate that IA produces a focal traumatic injury to RGC
axons in the intracranial portion of the optic nerve.
Seven days after injury, Gallyas silver staining revealed
extensive axonal degeneration, from the optic nerve and
tract to the superior colliculus (Fig. 2a-d). Degeneration
was associated with the presence of deramified/hyper-
trophic microglia (Fig. 2e-f). Semithin sections of the
optic nerve revealed numerous degenerative ovoids and
axonal loss at 2 weeks post-injury that was maintained
at 4 weeks (Figs. 3 and 4). Axonal degeneration profiles
differ between the proximal part of the nerve, close to
the eye, with the distal part of the nerve, close to the
chiasm. The distal nerve has more pronounced dysmye-
lination and more severe axonal loss compared to prox-
imal both at two- and four-weeks post injury. There is
ongoing degeneration in the distal segment between
two- and four-weeks post injury (Fig. 3d). At 4 weeks,
de- and dys-myelination were less evident distally, but
there was extensive myelin debris (Fig. 4c). To determine
if IA caused RGC death, we counted the number of
SNCG-positive cells in retinal flatmounts two- and four-
weeks post-injury and we found a progressive decrease
in the number of RGC somas in the course of the first
month (Fig. 5). Taken together, these results suggest that
the IA model produces a focal axonal injury that leads
to progressive axonal and somal RGC degeneration.
The DLK-JNK pathway is activated in RGCs in the course
of visual TAI
Based on previous work implicating DLK-JNK signaling
in RGC degeneration after optic nerve crush, we tested
whether a diffuse TBI model such as IA activates the
DLK-JNK cascade in a similar fashion. Since DLK levels
are indicative of pathway activation, we immunostained
retinal sections for DLK and also immunoblotted whole
retinal lysates. Both approaches showed transient upreg-
ulation of DLK, peaking around 1 day after injury
(Fig. 6a, c, e and Fig. 7). We did not pursue LZK IHC or
immunoblotting because of the lack of reliable anti-
bodies. To determine if this upregulation was associated
with pathway activation, we used immunoblotting and
IHC to measure the phosphorylation state of the down-
stream kinases MKK4, MKK7, JNK1–3, and the tran-
scription factor JUN. By 1 day and extending at least
until day three after injury, increased phosphorylation of
each of the DLK substrates, MKK4 and MKK7, was evi-
dent (Fig. 6b, d, f and Fig. 7). The time course of the
activation was slightly different between IHC and im-
munoblotting, with whole-retina immunoblotting failing
to detect the early increase likely because of the scarcity
of RGCs in whole-retinal samples. Nonetheless, both
Fig. 4 Details of traumatic axonopathy in the optic nerve at the
semithin level. Illustrated fields are from the same sections used for
Fig. 3. All panels are from toluidine blue-stained semithin sections of
the optic nerve proximal to the initial traumatic disruption of the
nerve (close to the eye; left panels) and distal to traumatic disruption
(towards the optic chiasm; right panels). The sham condition is illustrated in
(a), and representative fields from lesioned nerves two and 4 weeks post
injury are illustrated in (b) and (c). The main finding is myelin pathology
which is especially severe at 2weeks distally and 4weeks proximally. A lot of
abnormal myelin signal in the distal segment at 4weeks is in the form of
residual small myelin fragments. Note the prominent presence of astrocytes
in the proximal segment that have transformed into hypertrophic, reactive
profiles in (b) (asterisks). Scale bar: 10μm
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techniques showed a robust activation of JUN after in-
jury that returned to near baseline by 1 week (Fig. 7).
One confounding possibility is that RGCs with active
DLK signaling may die, thereby explaining the transient
kinase activation. To test this hypothesis, we double
stained retinal whole-mounts with antibodies against p-
JUN for pathway activation and the RGC marker SNCG
for viable neurons. The increased density of p-JUN-
positive RGCs at one, three, seven, and 14 days after IA
injury confirmed activation of the DLK-JNK axis (Fig. 8).
Moreover, between one and 14 days, there was a de-
crease in the number of live RGCs with JUN activation,
suggesting that kinase activation is transient for most
RGCs. Because our TBI model initially activates DLK-
JNK signaling in 75% of RGCs (Fig. 8d), but ultimately
only ~ 40% of RGC somas and axons die (Fig. 5), it is
likely that some fraction of RGCs are able to recover
from the injury and normalize the DLK signal. Retinal
ganglion cells with prolonged p-JUN expression appear
atrophic and with decreased SNCG expression, an indi-
cation that they may be degenerating neurons. This po-
tential recovery is surprising given that activation of the
DLK-JNK pathway in the optic nerve crush model is
sustained and leads to death of most RGCs [17]. In con-
trast, TBI leads to a robust initial activation of the DLK-
JNK pathway, which is partially reversed in the post-
acute phase of injury in surviving RGCs.
The activation of JUN in visual TAI is dependent on DLK
signaling
We have previously shown that DLK is the major MAP3K
input responsible for JNK activation in response to axotomy
in the optic nerve crush model, with additional contribution
from LZK [18, 19]. To explore the degree to which the same
kinases are responsible for JNK activation following the non-
transecting injury in the IA model, we turned to mice with
conditional alleles of Dlk and Lzk [18, 22]. Floxed Dlk or
floxed Dlk/Lzk (Dlkfl/fl and Dlkfl/flLzkfl/fl mice, respectively)
were intravitreally injected with AAV-Cre into one eye and a
control virus (AAV-GFP) into the fellow eye. After 2 weeks,
i.e. time sufficient for AAV to complete its lifecycle and trig-
ger recombination, mice were subjected to TBI with IA. We
then measured the rate of JUN phosphorylation as deter-
mined by the number of p-JUN (+) RGCs 3 days after injury
(when signaling peaks based on immunohistochemical and
immunoblot data). Compared to control animals (Fig. 9a),
Fig. 5 Progressive RGC loss after IA injury. In these whole-mount retinas stained with the RGC marker γ-synuclein (SNCG) 2 or 4 weeks after sham
(a) or IA injury (b-c), there is evident RGC loss. Insets in a and c show the retinal flat mounts from which images in main panels originated. Note
the progressive decrease in cell density from a to c. d. A bar graph with densities of surviving SNCG (+) RGCs 2 and 4 weeks post-injury, as
compared to sham. Data were analyzed with one-way ANOVA followed by Tukey’s post hoc test. * p < 0.05. Scale bars: a-c, 50 μm; inserts in a
and c, 100 μm
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eyes with a targeted disruption of DLK/LZK had a significant
(~ 75%) suppression of JUN phosphorylation (Fig. 9c, f).
Interestingly, similar suppression was seen with DLK disrup-
tion alone (Fig. 9e), suggesting that DLK is a primary medi-
ator of JNK activation in the IA model, and that LZK cannot
compensate for a loss of DLK.
Combined deletion of Dlk and Lzk increases survival of
RGCs in visual TAI
To test the role of DLK and LZK in cell death following IA, a
separate group of Dlkfl/fl and Dlkfl/flLzkfl/fl mice were injected
with AAV-Cre or AAV-GFP and RGC survival was quanti-
fied 30 days after injury. Deletion of Dlk failed to show a sig-
nificant effect on survival (Fig. 9g). However, combined
deletion of Dlk and Lzk was protective and significantly in-
creased survival of RGCs (Fig. 9b, d, h). These findings sug-
gest that DLK and LZK have redundant abilities to trigger
cell death in TAI, which differs from the ONC model in
which Dlk deletion alone is robustly protective [18].
Pharmacologic DLK/LZK inhibition improves RGC survival
in visual TAI
Since genetic disruption of DLK/LZK protected injured
RGCs, we asked whether pharmacological inhibition of
DLK and LZK could similarly improve RGC survival in
the IA model. Using published profiling data, we identi-
fied the FDA-approved protein kinase inhibitor sunitinib
as having activity against DLK and LZK, but not against
the downstream kinases MKK4, MKK7 and JNK1–3
[30]. Given that sunitinib penetrates the CNS [31], we
tested whether its administration could promote RGC
survival in the IA model. First, to confirm target engage-
ment, mice were treated with intraperitoneal sunitinib
(or the vehicle control) at 1 day and 4 h prior to injury,
and then once more on the day after injury. Retinas were
then harvested and stained for p-JUN. Sunitinib treat-
ment led to a significant decrease in the number of p-
JUN positive RGCs, confirming that it was able to par-
tially suppress JNK signaling (Fig. 10). We then repeated
the experiment, this time extending the treatment period
for 21 days and assaying for RGC survival using SNCG
staining of retinal whole-mount preparations. The re-
sults show that sunitinib treatment can improve neur-
onal survival following IA, increasing the number of
surviving RGCs from 1500 cells/mm2 to nearly 2300
cells/mm2 (p < 0.05, t-test) when compared to vehicle,
although the effect does not achieve normal (sham)
RGC densities (Fig. 10b).
Combined deletion of Dlk and Lzk protects optic nerve
axons early in the course of TAI-associated axonopathy
Having established the long-term protective effect of ei-
ther genetic or pharmacological DLK/LZK inhibition on
RGC survival, we explored the role of these kinases in
axonal degeneration produced by the IA model. Based
on stereological counts of myelinated axons in the optic
nerve proximal and distal to the putative site of injury
and comparisons between AAV-Cre and control AAV-
GFP-treated eyes, DLK deletion alone did not appear to
protect axons at 3 or 30 days post-injury. The combined
deletion of Dlk and Lzk protected optic nerve axons at 3
days after TBI, but this effect was not sustained at the
30-day time point post injury (Fig. 11). Taken together,
these results suggest that TAI-associated axonal degen-
eration in the visual system is not as dependent on the
DLK/LZK genetic program.
Discussion
Our study explores the role of two MAP3Ks, DLK and
LZK, in TAI-associated axonopathy and RGC degener-
ation in the visual system following IA injury. Traumatic
axonal injury in the visual system is featured by axonal
transport defects followed by axonal swellings and bulbs
in a segment of optic nerve. This is then followed by
progressive axonopathic changes (traumatic axonopathy)
leading to degeneration of a sizable portion of axons and
retrograde death of RGCs. Our findings indicate that
TAI in the visual system is associated with the activation
Fig. 6 Activation of the DLK-JNK axis in the retinas of IA-injured
mice. a, c, e. These horizontal retinal sections were processed for
DLK immunohistochemistry and demonstrate the induction of DLK
immunoreactivity in cell bodies (asterisks) in the ganglion cell layer
and in axons in the nerve fiber layer (arrows) 1 and 3 days post-
injury. There is very little immunoreactivity in sham retinas (a). b, d, f.
These sections were immunostained for p-JUN and show the
presence of many p-JUN (+) nuclei in the ganglion cell layer 1 and
3 days post-injury. Sham-injured retinas (b) are negative. Scale bars:
a-f, 50 μm
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of the DLK/LZK-JNK axis that is responsible, at least
in part, for RGC somal death, although its role in
axonal degeneration is limited. The conditional
knockout of Dlk and Lzk in adult mice employed here
precludes a neurodevelopmental compensation effect
on RGC survival and points to the central role of the
DLK-JNK axis in neurodegeneration after TBI. The
role of DLK/LZK in triggering RGC degeneration dur-
ing TAI is further supported by the neuroprotective
effect of the FDA-approved kinase inhibitor, sunitinib,
a finding with therapeutic potential. Our results show
that molecular signals operating in simple forms of
axonal injury, i.e. axotomy, play important roles in
some of the degenerative outcomes of TAI in the
CNS.
We have previously shown that our diffuse model of
TBI (IA) leads to multifocal TAI in the corticospinal
tract, optic nerve, gracile fasciculus, fornix, and corpus
callosum [11, 12]. Traumatic axonal injury in the visual
system is associated with optic nerve axonopathy (trau-
matic axonopathy) that is further characterized here and
has been shown to correlate with injury burden [11].
The primary biomechanical disruption of the optic nerve
corresponds to a region between the orbital apex and
the chiasm which is roughly used for the pathological
distinctions between “proximal” and “distal” in this
paper. Degenerating optic nerve axons show widespread
dysmyelination/demyelination that is evident as early as
3 days post-injury. Axonopathy is more severe distal to
the site of biomechanical disruption where it continues
Fig. 7 Expression of kinases in the DLK-JNK pathway in the retina after IA injury by Western blotting. Bar graphs at the bottom represent quantitation
of the intensity of protein bands for DLK, activated MKK4 and MKK7 ratios, p-JNK and p-JUN in the sham condition and at 1, 3, and 7 days post-injury.
Data were analyzed with one-way ANOVA followed by Tukey’s post hoc test. * p < 0.05
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to evolve over the course of the 4-week period exam-
ined in our study. Compared to the effects of IA in
other CNS tracts, e.g. the corticospinal tract, a dis-
tinct feature of TAI in the optic nerve is the retro-
grade degeneration of neurons (RGCs), in keeping
with the classical vulnerability of these nerve cells to
death after axonal lesions [32–34]. This notion is
further supported by the fact that progression of
death of RGC somata appears to lag behind the wave
of axonal degeneration. The co-registration of rates of
death in RGCs and in proximal axons, both of which
are ~ 25–30%, may suggest a biological correlation
between degeneration of perikarya and degeneration
of proximal axons.
Fig. 8 Quantitative assessment of DLK-JNK activation after IA injury based on counts of p-JUN (+) RGCs. a-c. In whole-mount retinas dually
stained for the RGC marker γ-synuclein (SNCG) (red) and the DLK-JNK marker p-JUN (green), there is induction of p-JUN in RGCs at day 1 (b) and
attenuation of labeling by day 14 (c). No p-JUN (+) RGCS are seen in the sham scenario (a). Left-sided images have been acquired with green
filter combination for red SNCG immunofluorescence, images at the center have been acquired with blue filter combination for green p-JUN
immunofluorescence, and panels on the right are merged images in which double-labeled profiles appear orange. Note the extensive colocalization at
day 1, based on the large number of orange profiles (b, right panel). Most p-JUN (+) nuclei at day 14 seem to belong to smaller or atrophic RGCs (c).
d-e. Bar graphs of densities of p-JUN (+) RGCs in the retinas of sham and injured animals at 1, 3, 7, and 14 days post-injury (d), and of the ratios of
densities of p-JUN (+) RGCs over densities of total RGCs from two representative time points, i.e. 1 and 14 days (e). Significant differences are indicated
with asterisks. The comparison in (e) was done to ensure that reduction in numbers of double labeled profiles in (d) was not simply an artifact of the
progressive death of RGCs. Data were analyzed with one-way ANOVA followed by Tukey’s post hoc test for (d) and with student’s t-test for (e). * p <
0.05. Scale bars: 25 μm
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Fig. 9 (See legend on next page.)
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DLK is part of a highly-conserved retrograde injury
signal that is triggered by axotomy, leading to the activa-
tion of both apoptotic and regenerative processes [17,
19, 21, 35]. However, simple axotomy models (e.g. optic
nerve crush) differ from more clinically relevant models,
e.g. TAI, in that the latter tend to produce more graded
and incomplete axonal injury. The degree to which DLK
is required for TBI- and TAI-associated axonopathy had
not been previously explored. Our results suggest some
key similarities and differences. As with axotomy, TAI
leads to upregulation of DLK and activation of the
MKK/JNK/JUN signaling pathway in RGCs. Moreover,
DLK acts as obligatory upstream mediator of JUN acti-
vation, because targeted disruption of DLK leads to a
near-total suppression of JUN phosphorylation. Perhaps
the most important difference is that the TAI model
triggers DLK activation in such a way that a subset of
RGCs can recover and terminate the signal. The mech-
anism by which this phenomenon occurs is probably re-
lated to subthreshold biomechanical injury in a large
number of optic nerve axons but may also involve select-
ive vulnerability of subclasses of RGC neurons. These is-
sues need to be explored further because they may have
important implications for RGC neuroprotection in the
context of TBI.
Furthermore, in contrast to axotomy models in which
deletion of Dlk by itself rescues the survival of ~ 75% of
RGCs [16, 17, 19] in the TAI model, knockout of Dlk
has little effect on RGC survival. Only when both DLK
and LZK were targeted did we see an increase in RGC
survival, suggesting a degree of genetic redundancy for
these two highly-related kinases. Not surprisingly, the
degree of redundancy seems to be dependent on the
model, with the TAI model and primary RGC cultures
showing a large degree of DLK/LZK redundancy (i.e.
combined inhibition is required for robust survival),
while the ONC model shows a lesser degree of redun-
dancy (i.e. combined disruption produces a more modest
increase in survival over Dlk disruption alone). It is also
interesting to note that deletion of Dlk with or without
Lzk leads to a significant reduction in the downstream
phosphorylation of JUN but only the combined deletion
of the two protects RGC viability. Although we cannot
exclude effects on the kinetics or localization of JNK ac-
tivation, these data could indicate that LZK may be
upstream of an as-yet-unidentified pathway responsible
for RGC cell death in TAI.
In order to develop an expedited route to clinically
evaluate DLK/LZK inhibition as a neuroprotective strat-
egy, we previously surveyed FDA-approved protein kin-
ase inhibitors for ones with activity against DLK and
LZK. This approach identified sunitinib (Sutent®), FDA-
(See figure on previous page.)
Fig. 9 The effects of Dlk or combined Dlk/Lzk deletion on JNK signaling and RGC survival after IA injury. Subjects were Dlkfl/fl or Dlkfl/flLzkfl/fl mice.
As elsewhere in this paper, p-JUN expression was used as a marker of DLK-JNK activation. Retinal ganglion cells were labeled with RBPMS. a-d.
Representative images of p-JUN (a, c) and RBPMS (b, d) immunostained retinas in which Dlk and Lzk was deleted (AAV-Cre-GFP, c-d) and retinas
from fellow eyes in which Dlk and Lzk were left intact (AAV-GFP, a-b). Images illustrate the suppression of p-JUN immunoreactivity at day 3 post-
injury (c) and improved RGC survival 30 days post-injury (h) with combined Dlk/Lzk deletion. e-h. Bar graphs with quantitative assessments of the
effects of Dlk or Dlk/Lzk deletion on p-JUN expression measured at day 3 after injury (e and f, respectively) and also the effects of Dlk or Dlk/Lzk
deletion on RGC survival measured 30 days after injury (g and h, respectively). Scale bars: a-d, 25 μm
Fig. 10 Suppression of JNK signaling and promotion of RGC survival
by sunitinib in the IA model. a As elsewhere in this paper, DLK-JNK
activation in retina was marked by density of p-JUN immunoreactivity in
retinal flatmounts that here was measured at day 1 post injury. b Survival
was based on the density of SNCG (+) cells that was measured 3weeks
post injury. Data were analyzed with one-way ANOVA followed by Tukey’s
post hoc test. * p <0.05, **p <0.01, ***p <0.001
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Fig. 11 Combined Dlk/Lzk deletion using Dlkfl/flLzkfl/fl mice delays axonal degeneration in the optic nerve. a-b. Representative images from
semithin sections of the proximal optic nerve 3 days post injury showing the protective effect of Dlk/Lzk deletion. Cre-treated optic nerve is
depicted on the right (b) and control optic nerve from the fellow eye is shown on the left (a). c-j. Bar graphs with counts of axons in the optic
nerve proximal (c-d and g-h) and distal (e-f and i-j) to the site of the initial traumatic disruption three (c-f) and 30 (g-j) days post injury in Dlkfl/fl
(c, e, g, i) or Dlkfl/flLzkfl/fl (d, f, h, j) mice treated with Cre or control (GFP) vectors in the two eyes. There are eight combinations of genotype ×
proximal or distal location × early or late time point post injury. Of all combinations, the only significant effect on axonal degeneration is that of
the deletion of both Dlk and Lzk in the proximal nerve early post injury (d). Data were analyzed with student’s t-test. * p < 0.05. Scale bars:
a-b, 25 μm
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approved for renal cell carcinoma and gastrointestinal
stromal tumor, as having high nanomolar IC50 for both
DLK and LZK. Moreover, we showed that sunitinib in-
creased the survival of induced pluripotent stem cell
(iPSC)-derived human RGCs [18]. Here we have ex-
tended these findings to demonstrate that pharmaco-
logical blockade of DLK and LZK with sunitinib
increases RGC survival in vivo in a rodent TBI model.
To these authors’ knowledge, and with the possible
exception of antioxidants [36], this is the first demon-
stration of an FDA-approved compound decreasing
neuronal cell death in a TBI model.
Central nervous system tracts other than the visual
system that are vulnerable to TAI and succumb to trau-
matic axonopathy [12] may also use DLK-dependent in-
jury signals; therefore, our findings raise the prospect of
using protein kinase inhibitors as part of a neuroprotec-
tive strategy for TBI. Traumatic brain injury very com-
monly affects axons and the state of axons after injury is
important for the integrity of neuronal circuitry and the
function of neural networks [37]. After we established
that RGC somatic death is, at least in part, a DLK/LZK-
dependent phenomenon, we explored the effect of the
DLK/LZK pathway on axonal survival. DLK appears to
be implicated in axonal degeneration through a negative
effect on levels of SCG10, an anterogradely transported
protein that promotes axonal survival after axotomy
in vitro [38]. More recently, the involvement of DLK in
axonal degeneration has been examined in vitro using
primary dorsal root ganglion neurons [23]. These experi-
ments have revealed an important role of DLK in main-
taining basal levels of NMNAT2, an essential axonal
survival factor, through the degradation of the palmitoy-
lated form of the enzyme under normal conditions. De-
letion of Dlk raises basal level of anterogradely
transported NMNAT2 prior to injury, and thus delays
axonal degeneration. This protective effect is more pro-
nounced when combined with deletion of the Phr1/
Skp1a/Fbxo45 ligase complex that is important for the
degradation of the nonpalmitoylated fraction of
NMNAT2 [23]. Consistent with these observations, we
found that the combined deletion of Dlk and Lzk only
protected optic nerve axons from degeneration early, i.e.
3 days, post injury. To our knowledge, this is the first
demonstration that LZK plays a role, albeit limited, in an
active axonal degeneration program. This finding is in
line with the kinetics of NMNAT2, a labile protein that
needs continuous replenishment to exert protective ef-
fects on axons [39]. The blockade of anterograde trans-
port that occurs with TAI would have prevented the
axonal transport of NMNAT2, leaving the axon only
with basal levels of the protein, which may be higher
is neurons with deleted Dlk/Lzk. This effect, however,
may not be sufficient to completely protect injured
axons, as suggested by the fact that there is no sig-
nificant effect on survival at 30 days post injury.
Conclusion
Here we have shown the RGC loss after TBI can be pre-
vented, at least in part, by the genetic deletion or
pharmacological inhibition of DLK/LZK. This finding
may be an important step in protecting RGCs in the
context of TBI and potentially allowing them to reinte-
grate into the visual circuitry if many axons are still rela-
tively intact or if regenerative strategies become more
effective in the future [40]. We also showed that by
blocking DLK/LZK we may delay degeneration of RGC
axons although, as has been also shown in simple axot-
omy lesions, the effect on RGC somata is clearly more
robust [16, 41–43]. Finally, here we showed that an
FDA-approved drug, sunitinib, with activity against both
DLK and LZK, is able to increase RGC survival in a TBI
model. Although future work will need to establish if
pharmacologic DLK/LZK inhibition can prevent degen-
eration when given in a more clinically-relevant post-
injury paradigm, our findings already suggest that this
intervention may be a promising lead for translational
efforts in the field of TBI.
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